Analgesia, sedation, and therapeutic paralysis in the critically ill

Seminars in Respiratory and Critical Care Medicine

Volumn 18, Issue 1, 1997, Pages 39-63

  Wheeler, Arthur P ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ANALGESIC AGENT; ANXIOLYTIC AGENT; ATRACURIUM; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; DIMETHYLTUBOCURARINE CHLORIDE; DOXACURIUM; FENTANYL; HALOPERIDOL; LORAZEPAM; MIDAZOLAM; MORPHINE; NEUROMUSCULAR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE ANTAGONIST; OPIATE DERIVATIVE; PANCURONIUM; PETHIDINE; PHENOTHIAZINE DERIVATIVE; PIPECURONIUM; PROPOFOL; REMIFENTANIL; ROCURONIUM; SEDATIVE AGENT; SUFENTANIL; SUXAMETHONIUM; UNINDEXED DRUG; VECURONIUM;

ANALGESIA; CRITICAL ILLNESS; DRUG CHOICE; DRUG USE; HUMAN; INTENSIVE CARE; PAIN; PARALYSIS; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SEDATION; SLEEP DISORDER;

EID: 0030992802     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1009332     Document Type: Review

References (323)

1. Bergbom-Engberg I, Haljave H. Assessment of patients' experiences of discomfort during respiratory therapy. Crit Care Med 1989;17:1068-72
2. Inensee LM, Weiner LJ, Hart RG. Neurologic disorders in a medical ICU: a prospective survey. J Crit Care 1989;4: 208-10
3. Adams F. Emergency intravenous sedation of the delirious medically ill patient. J Clin Psychiatr 1988 (Suppl);49: 22-6
4. McCarthy JR, Boland R. Understanding and managing behavioral disorders in the ICU. J Crit Illness 1993;8:87-93
5. Krachman SL, D'Alonzo GE, Criner GJ. Sleep in the intensive care unit. Chest 1995;107:1713-20
6. Steiner H, Clark WR. Psychiatric complications of burned patients: a classification. J Trauma 1977;17:134-43
7. Dracup K. Are critical care units hazardous to health? Appl Nurs Res. 1988;1:14-21
8. Myers TJ, Eveloff SE, Bauer MS, et al. Adverse environmental conditions in the respiratory and medical ICU settings. Chest 1994;105:1211-16
9. Marks W. Physical restraints in the practice of medicine: current concepts. Arch Int Med 1992;152:2203-6
10. Bion JF, Leddingham IMA. Sedation in intensive care. Atracurium - a postal survey Intensive Care Med 1986; 12:215-6
11. Aitkenhead AR. Analgesia and sedation in intensive care. Br J Anaesth 1989;63:196-206
12. Freeman JW, Hopkinson RB. Therapeutic Progress in intensive care sedation and analgesia. Part I-principles. J Clin Pharm Therap 1988;13:33-40
13. Freeman JW, Hopkinson RB. Therapeutic progress in intensive care sedation and analgesia. Part II-drug selection. J Clin Pharm Therap 1988;13 41-51
14. Crippen DW. The role of sedation in the ICU patient with pain and agitation Crit Care Clin 1990;6:369-92
15. Edwards WT, Burney RG, Kupferberg IM. Management of pain, anxiety, and psychosis in the critically ill. In: Rippe JM, Irwin RS, Alpert JS, Dalen JE, eds. Intensive Care Medicine. Boston: Little, Brown; 1985:1014-28
16. Dobb GJ, Murphy DF. Sedation and analgesia during intensive care. Clin Anesth 1985;3:1055-85
17. Murray MJ. Pain problems in the ICU. Crit Care Clin 1990; 6:235-53
18. Dasta JF, Fuhrman TM, McCandles C. Patterns of prescribing and administering drugs for agitation and pain in patients in a surgical intensive care unit. Crit Care Med 1994;22:974
19. Hansen Fleishen JH, Barzinsky S, Basile C, et al. Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure: a national survey. JAMA 1991;226:2870-75
20. Rockoff MA, Marshall LF, Shapiro HM. High dose barbiturate therapy in humans: a clinical review of 60 patients. Ann Neurol 1979;6:194
21. Gramstad L. Atracurium, vecuronium and pancuronium in end-stage renal failure: dose response properties and interactions with azathioprine. Br J Anaesth 1987;59:995-1003
22. Cheng EY The cost of sedating and paralyzing the critically ill patient. Crit Care Clin 1995;11:1005-19
23. Lutz LJ, Lamer TH. Management of postoperative pain: review of current techniques and methods. Mayo Clin Proc 1990;65:584-96
24. White PF. Use of patient controlled analgesia for management of acute pain. JAMA 1988;259:243-7
25. Graves DA, Foster TS, Batenhorst RL, et al. Patent controlled analgesia. Ann Intern Med 1983;99:360-6
26. Chamberlain JM, Klein BL, A comprehensive review of naloxone for the emergency physician. Am J Emerg Med 1994;12:650-60
27. Weinbroum A, Rudick V, Sorkine P, et al. Use of flumazenil in the treatment of drug overdose: a double blind and open clinical study in 110 patients. Crit Care Med 1996; 24:199-206
28. Pepperman ML. Double-blind study of the reversal of midazolam-induced sedation in the intensive care unit with flumazenil (Ro 15-1788); effect on weaning from ventilation. Anaesth Intensive Care 1990;18:38-44
29. Bodenham A, Park GR. Reversal of prolonged sedation using flumazenil in critically ill patients. Anesthesia 1989; 44:603-5
30. Rupp SM, McChristian JW, Miller RD, Taboada JA, Cronnelly R. Neostigmine and edrophonium antagonism of varying intensity neuromuscular blockade induced by atracurium, pancuronium, or vecuronium. Anesthesiology 1986;64:711-7
31. Buzello W. Postoperative care: antagonism of drugs used in anesthesia: muscle relaxants. Acta Anaesthesiol Scand 1988;32(Suppl 87):25-7
32. Cronnelly R, Morris RB. Antagonism of neuromuscular blockade. Br J Anesth 1982;54:183-94
33. Engbaek J, Ostergaard S, Skovgaad LT, Viby-Mogensen J. Reversal of intense neuromuscular blockade following infusion of atracurium. Anesthesiology 1990;72:803-6
34. Kopman AF. Recovery times following edrophonium and neostigmine reversal of pancuronium, atracurium, and vecuronium steady state infusions. Anesthesiology 1986; 65:572-8
35. Ferguson A, Egerzegi P, Bevan DR. Neostigmine, pyridostigmine, and edrophonium as antagonists of pancuronium. Anesthesiology 1980;53:390
36. Byatt CM, Lewis LD, Dawling S, Cochrane GM. Accumulation of midazolam after repeated dosage in patients receiving mechanical ventilation in an intensive therapy unit. Br Med J 1984;289:799-800
37. Byrne AJ, Yeoman PM, Mace P. Accumulation of midazolam in patients receiving mechanical ventilation. Br Med J 1984;289:1309
38. Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet 1983;8:422-8
39. Shelly MP, Mendel L, Park GR. Failure of critically ill patients to metabolize midazolam. Anesthesia 1987;42: 619-26
40. Dundee JW, Collier PS, Carslile RJT, Harper KW. Prolonged midazolam elimination half-life. Br J Clin Pharmacol 1986;21:425-9
41. Partridge BL, AbramsJH, Bazemore C, Rubin R. Prolonged neuromuscular blockade after long-term infusion of vecuronium bromide in the intensive care unit. Crit Care Med 1990;18:1177-9
42. Segredo V, Matthay MA, Sharma ML, Gruenke LD, Caldwell JE, Miller RD. Prolonged neuromuscular blockade after long term administration of vecuronium in two critically ill patients. Anesthesiology 1990;72:566-70
43. Parker MM, Schubert W, Shelhamer JH. Perceptions of a critically ill patient experiencing therapeutic paralysis in an ICU. Crit Care Med 1984;12:69-71
44. Loper KA, Butlwer S, Nessly M, Wild L. Paralyzed with pain: the need for education. Pain 1989;37:315-6
45. Blacher RS. On awakening paralyzed during surgery: A syndrome of traumatic neurosis. JAMA 1975;234:67
46. Anonymous. On being aware. Br J Anaesth 1979;51:711-2 (Editorial)
47. Kenny GN. Potential renal, hematological and allergic adverse effects associated with nonsteroidal anti-inflammatory drugs. Drugs 1992;44(Suppl 5):31-6
48. Saxen MA. The clinical pharmacology of ketorolac. Compendium 1992;13:504-9
49. DeAndrade JR, Maslanka M, Maneatis T, et al. The use of ketorolac in the management of post-operative pain. Orthopedics 1994;17:157-66
50. Schein R, Quartin A, Kett D, et al. Acute renal failure among patients with severe sepsis. Am J Respir Crit Care Med 1996;153:A833
51. Wong KC. Narcotics are not expected to produce unconsciousness and amnesia. Anesth Analg 1983;62:625
52. Stanford TJ, Smith NT, Dec-Silver H, Harrison WK. A comparison of morphine, fentanyl and sufentanil anesthesia for cardiac surgery. Induction, emergence and extubation. Anesth Analg 1986;65:259
53. Lowenstein E, Hallowell P, Levine FH, Daggett WM, Austeng G, Laver MB. Cardiovascular response to large doses of intravenous morphine. N Engl J Med 1969;281: 1389
54. Arunasalam K, Davenport HF, Painter S, Jones JG. Ventilatory response to morphine in young and old subjects. Anesthesia 1983;38:529-33
55. Rouby JJ, Eurin B, Glaser P, Guillosson JJ, Guesde R, Viars P. Hemodynamic and metabolic effects of morphine in the critically ill. Circulation 1981;64:530-9
56. Weil JV, McCullough RE, Kline JS, Sodal IE. Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man. N Engl J Med 1975;292:1103
57. Eckenhoff JE, Oech SR. The effects of narcotics and antagonists upon respiration and circulation in man. Clin Pharamacol Ther 1960;1:483
58. Rosow CE, Moss J, Philbin DM, Savarese JJ. Histamine release during morphine and fentanyl anesthesia. Anesthesiology 1982;56:93
59. Bion JF, Logan BK, Newman PM. Sedation in intensive care: Morphine and renal function. Intensive Care Med 1986; 12:359-65
60. Cicala RS, Voeller GR, Fox T, et al. Epidural analgesia in thoracic trauma: effects of lumbar morphine and thoracic bupivacaine on pulmonary function. Crit Care Med 1990;18:229-31
61. Cousins MJ, Ather LE. Intrathecal and epidural administration of opioids. Anesthesiology 1984;61:276
62. Behar M, Olshwang D, Magora F, Davidson JT. Epidural morphine in the treatment of pain. Lancet 1979;1:527-9
63. Crews JC. Epidural opioid analgesia. Crit Care Clin 1990; 6:315
64. Eisenach JC, Grice SC, Dewan DM. Patients controlled analgesia following cesarean section: A comparison with epidural and intramuscular narcotics. Anesthesiology 1988;68:444-8
65. Frank ED, McKay W, Rocco A, Gallo JP Intrapleural bupivacaine for postoperative analgesia following cholecystectomy: a randomized prospective study. Reg Anesth 1990; 15:26-30
66. Faust RJ, Nauss L. Post thoracotomy intercostal block: comparisons of its effect on pulmonary function with those of intramuscular meperidine. Anaesth Analg 1976;55:542-6
67. Majid AA, Hamzah H. Pain control after thoracotomy. Chest 1992;101:981-4
68. Lunn JK, Stanley TH, Eisele J, Webster L, Woodward A. High dose fentanyl anesthesia for coronary artery surgery. Anesth Analg 1979;58.L390
69. Shafer A, White PF, Schuttler, Rosenthal MH. Use of fentanyl infusion in the intensive care unit: tolerance to its anesthetic effects. Anesthesiology 1983;59:245-8
70. Nimmo WS, Todd JG. Fentanyl by constant rate I.V. infusion for postoperative analgesia. Br J Anesth 1985;57: 250-4
71. Bodenham A Shelly MP, Park GR. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet 1988;14: 347-73
72. Streisand JB, Bailey PL, LeMaire L, et al. Fentanyl-induced rigidity and unconsciousness in human volunteers. Incidence, duration and plasma concentrations. Anesthesiology 1993;78:629-34
73. Yee LY, Lopez JR. Transdermal fentanyl. Ann Pharmacother 1992;26:1393-9
74. Bodenham A, Park GR. Alfentanil infusion in patients requiring intensive care. Clin Pharmacokinet 1988;15:216-26
75. Sinclair ME, Sear JW, Summerfield RJ. Alfentanil infusions on the intensive therapy unit. Intensive Care Med 1988; 14:55-9
76. Van Peer A, Vercauteren M, Noorduin R, Woestenborghs R, Heykants J. Alfentanil kinetics in renal insufficiency. Eur J Clin Pharmacol 1986;30:245-7
77. Cohen AT, Kelly DR. Assessment of alfentanil by intravenous infusion as long term sedation in intensive care. Anesthesia 1987;42:545-8
78. Helmers JH, van Leeuwen L, Zuurmond WW. Sufentanil pharmacokinetics in your adult and elderly surgical patients. Eur J Anaesthesiol 1994;11:181-5
79. Willens JS, Myslinski NR. Pharmacodynamics, pharmacokinetics and clinical uses of fentanyl, sufentanil and alfentanil. Heart Lung 1993;22(4):307
80. Burkle H, Dunbar S, Van Aken H. Remifentanil: a novel short acting mu-opoid. Anesth Analg 1996;83:646-51
81. Glass PS. Remifentanil: a new opioid. J Clin Anesth 1995; 7:558-63
82. Egan TD. Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. Clin Pharmacokinet 1995;29:80-94
83. Clark RF, Wei EM, Anderson PO. Meperidine: therapeutic use and toxicity. J Emerg Med 1995;13:797-802
84. Dundee JW, Johnston HM, Gray RC. Lorazepam as a sedative-amnestic in an intensive care unit. Curr Med Res Opin 1976;4:290-5
85. Dundee JW, Halliday NJ, Harper KW, Brogden RN. Midazolam-A review of its pharmacological properties and therapeutic use. Drugs 1984;28-519-43
86. Abel RM, Reis RL. Intravenous diazepam for sedation following cardiac operations: clinical and hemodynamic assessments. Anesth Analg 1971;50:244-8
87. Kumar A, Bleck TOP. Intravenous midazolam for the treatment of refractory status epilepticus. Crit Care Med 1992;20:483-8
88. Finley PR, Nolan PE. Precipitation of benzodiazepine withdrawal following sudden discontinuation of midazolam. DICP 1989;23:151-2
89. Driessen JJ, Crul JF, Vree TB, Van Egmond J, Booij HDJ. Benzodiazepines and neuromuscular blocking drugs in patients. Acta Anesthesiol Scand 1986;30:642-6
90. Bertilsson L, Baillie TA, Reviriego J. Factors influencing the metabolism of diazepam. Pharmacol Therap 1990;45: 85-91
91. Shapiro J, Westphal LM, White PF, Sladen RN, Rosentahl MH. Midazolam for sedation in the intensive care unit - Effect on adrenal function. Anesthesiology 1986;64: 394-8
92. Oldenhot H, Dejong M, Setthoek A, Janknegt R. Clinical Pharmacokinetics of midazolam in intensive care patients: A wide interpatient variability? Clin Pharmacol Ther 1988;43:263-9
93. Malacrida R, Fritz ME, Suter PM, Crevoisier C. Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. Crit Care Med 1991;20:1123-6
94. Pohlman AS, Simpson KP, Hall JB. Continuous intravenous infusions of lorazepam versus midazolam for sedation during mechanical ventilatory support: a prospective randomized study Crit Care Med 1994;22:1241-8
95. Ariano RE, Kassum DA, Aronson KJ. Comparison of sedative recovery time after midazolam versus diazepam administration. Crit Care Med 1994;22:1492-7
96. Dundee JW, Lilburn JK, Nair SG, et al. Studies of drugs given before anesthesia XXVI: Lorazepam. Br J Anaesth 1977;49:1047
97. McKay AC, Dundee JW. Effects of oral benzodiazepines on memory. Br J Anaesth 1980;52:1247-51
98. Amrein R, Hetzel W, Hartman S, Lorscheid T. Clinical pharmacology of flumazenil. Eur J Anaesth 1988;(suppl 2): 65-80
99. Mordel A, Winkler E, Almog S, Triosh M, et al. Seizures after flumazenil administration in a case of combined benzodiazepine and tricyclic antidepressant overdose. Crit Care Med 1992;201:1733-4
100. Lund N, Papadakos PJ. Barbiturates, neuroleptics and propofol for sedation. Crit Care Clin 1995;11:875-86
101. Dundee JW, Wyant GM. Intravenous Anesthesia 2nd ed. New York: Churchill Livingstone; 1988:97-134
102. McCullough R, Cohen PJ, Weil JV. Effect of pentobarbitone on hypoxic ventilatory drive in man. Br J Anaesth 1975; 47:963-8
103. Stanski DR, Hihm FG, Rosenthal MH, Kalman SM. Pharmacokinetics of high dose thiopental used in cerebral resuscitation. Anesthesiology 1980;53:169-71
104. Eckstein JW, Hamilton WK, McCammond JM. The effect of thiopental on peripheral venous tone. Anesthesiology 1961;22:535-8
105. Turcant A, Delhumeau A, Prcmil-Cabic A, et al. Thiopental pharmacokinetics under conditions of long term infu-sion. Anesthesiology 1985;63:50-4
106. Olson RW. Barbiturates. Int Anesthesiol Clin 1988;26:254
107. Browne TR. The pharmacokinetics of agents used to treat status epilepticus. Neurology 1990;40(suppl 2):28-32
108. Lowenstein DH, Aminoff MJ, Simon RP. Barbiturate anesthesia in the treatment of status epilepticus: clinical experience with 14 patients. Neurology 1988;38:395-400
109. Ziehm SR. Intravenous haloperidol for tranquilization in critical care patients: a review and critique. AACN Clin Issues 1987;2:278-80
110. Ayd FJ. IV haloperidol: an update. Int Drug Ther Newsletter 1988;23:33-5
111. Riker RR, Fraser GI, Cox PM. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med 1994;22:433-40
112. Adams F. Emergency intravenous sedation of the delirious medically ill patient. J Clin Psychiatr 1988;49(suppl):22-6
113. Adams F, Fernandez F, Anderson BS. Emergency pharmacotherapy of delirium in the critically ill cancer patient. Psychosomatics 1986;27(suppl):33-7
114. Yeh BK, McNay JL, Goldberg LI. Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: evidence for a specific dopamine receptor. J Pharmacol Exp Ther 1969;168:303-9
115. Armstrong DK, Dasta JF, Reilley Te, et al. Effect of haloperidol on dopamine-induced increases in renal blood flow. Drug Intell Clin Pharm 1986;20:543-6
116. Saunders KM. Low incidence of extra pyramidal symptoms in treatment of delirium with intravenous haloperidol and lorazepam in the intensive care unit. J Int Care 1989; 4(5):201-4
117. Levitt AJ, Midha R, Craven JL. Neuroleptic malignant syndrome with intravenous haloperidol. Can J Psychiatry 1990;35:789
118. Konikoff F, Kuritszky A, Jerushalmi Y, et al. Neuroleptic malignant syndrome induced by a single injection of haloperidol. Br J Med 1984;289:1228-9
119. Barach E, Dubin LM, Tomlanovich MC, et al. Dystonia presenting as upper airway obstruction. J Emerg Med 1989; 7:237-40
120. Mann SC, Cohen MM, Boger WP. The danger of laryngeal dystonia. Am J Psychiatry 1979;136:1344-5
121. Zeifman CWE, Friedman B. Torsades de pointes: potential consequence of intravenous haloperidol in the intensive care unit. Int Care World 1994;11:109-12
122. Wilt JL, Minnema AM, Johnson RF, Rosenblum AM. Torsades de Pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993;119:391-4
123. Fayer SA Torsades de pointes ventricular arrhythmia associated with haloperidol. J Clin Psychopharmacol 1986;6: 375-6
124. Kriwisky M, Perry GY, Tarchitsky D, et al. Haloperidol induces torsades de pointes. Chest 1990;98:482-4
125. Mirenda J, Broyles G. Propofol as used for sedation in the ICU. Chest 1995;108-539-48
126. Newman LH, McDonald JC, Wallace PGM, et al. Propofol infusion for sedation in intensive care. Anaesthesia 1987; 42:929-37
127. Albanese J, Martin C, Lacarelle B, et al. Pharmacokinetics of long term propofol infusion used for sedation in ICU patients. Anesthesiology 1990;73:214-7
128. Beller JP, Pottecher T, Lugnier A, et al. Prolonged sedation with propofol in ICU patients: recovery and blood concentration changes during periodic interruptions in infusion. Br J Anaesth 1988;69:240-5
129. Carrasco G, Molina R, Costa J, et al. Propofol versus midazolam in short-, medium-, and long-term sedation of critically ill patients. Chest 1993;103:557-64
130. Grounds RM, Lalor JM, Lumley J, et al. Propofol infusion for sedation in the intensive care unit: preliminary report. Br Med J 1987;294:397-400
131. Farting A, Johnston JR, Coppel DL. Propofol infusion for sedation of patients with head injury in intensive care: a preliminary report. Anaesthesia 1989;44:222-6
132. Pinaud M, Lelausque JN, Chetanneau A, et al. Effects of propofol on cerebral hemodynamics and metabolism in patients with brain trauma. Anesthesiology 1990;73:404-9
133. Mackenzie SJ, Kapadia F, Grant IS. Propofol infusion of control of status epilepticus. Anesthesia 1990;45:1043-5
134. Wood PR. Propofol infusion for the treatment of status epilepticus. Lancet 1988;1:480-1
135. Yanny HF. Propofol infusions for status epilepticus. Anaesthesia 1988;43:514
136. El-Ebiary M, Torres A, Ramirez J, et al. Lipid deposition during the long-term infusion of propofol. Crit Care Med 1995;23:1928-30
137. Valente JF, Anderson GL, Branson RD, et al. Disadvantages of prolonged propofol sedation in the critical care unit. Crit Care Med 1994;22:710-2
138. Bennett SN, McNeil MM, Bland LA, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med 1995;333:147-54
139. Nichols RL, Smith JW. Bacterial contamination of an anaesthetic agent. N Engl J Med 1995;333:184-5
140. Lingle CJ, Steinhach JH. Neuromuscular blocking agents. Int Anesth Clin 1988;26:288-301
141. Torda TA. The neuromuscular blocking drugs. Med J Austral 1988;149:316-9
142. Lee C, Katz RL. Neuromuscular pharmacology: A clinical update and commentary. Br J Anesth 1980;52:173-88
143. Buck ML, Reed MD. Use of non-depolarizing blocking agents in mechanically ventilated patients. Clin Pharm 1991;10:32-48
144. Klessig HT, Geiger HG, Murray MJ, Coursin DB. A national survey on the practice of anesthesiologist intensivists in the use of muscle relaxants. Crit Care Med 1992;20:1341-5
145. Miller-Jones CMH, Williams JH. Sedation for ventilation. A retrospective study of fifty patients. Anesthesia 1980;35: 1104-7
146. Stark AR, Bascom R, Frantz ID. Muscle relaxation in mechanically ventilated infants. J Pediatr 1979;94:439-43
147. Hunter JM. Neuromuscular blocking drugs in intensive therapy. Intensive Ther Clin Monitoring 1989;27:143-147
148. McHugh LG, Anardi DM, Bachenberg K, Goodrich C, Wild L, Pavlin EG. The use of neuromuscular blocking agents in ICU patients. Am Rev Respir Dis 1991;143:A695
149. Fiamengo SA, Savaraese JJ. Use of muscle relaxants in intensive care units. Crit Care Med 1991;19:1125-30
150. Willatts S. Indications for paralysis in ventilated patient. Acta Anesthesia (Belgium) 1988;39(Suppl):231-4
151. Peat SJ, Potter DR, Hunter JM. The prolonged use of atracurium in a patient with tetanus. Anesthesia 1988;43: 962-3
152. Coggeshall JW, Marini JJ, Newman JH. Improved oxygenation after muscle relaxation in adult respiratory distress syndrome Arch Intern Med 1985;145:1718-20
153. Marcy TW, Marini JJ. Inverse ratio ventilation in ARDS: Rationale and implementation. Chest 1991;100:494-504
154. Froese AB, Bryan AC. Effects of anesthesia and paralysis on diaphragmatic mechanics in man. Anesthesiology 1974; 41:242-55
155. Bishop MJ. Hemodynamics and gas exchange effects of pancuronium bromide in sedated patients with respiratory failure. Anesthesiology 1984;60:369-71
156. Ali HH, Savarese JJ. Monitoring of neuromuscular function. Anesthesiology 1976;45:216
157. Hoyt JW. Neuromuscular blockade in critical care. New Horizons 1994;2:1-120
158. Isenstein Da, Venner DS, Duggan J. Neuromuscular blockade in the intensive care unit. Chest 1992;102:1258-66
159. Shelly MP, Dodds P, Park GR. Assessing sedation. Care Crit III 1986;3:170
160. Sun X, Quinn T, Weissman C. Patterns of sedation and analgesia in the postoperative ICU patient. Chest 1992;101: 1625-32
161. Martyn J, Goldhill DR, Goudsouzian NG. Clinical pharmacology of muscle relaxants in patients with burns. J Clin Pharmacol 1986;26:680-5
162. Martyn JAJ, Matteo RS, Greenblatt DJ, Lebowitz PW, Savarese JJ. Pharmacokinetics of d-tubocurarine in patients with thermal injury. Anesth Analg 1982;61:241-6
163. Martyn JAJ, Matteo RS, Szyfelbein SK, Kaplan RF. Unprecedented resistance to neuromuscular blocking effects of metocurine with persistence after complete recovery in a burned patient. Anesth Analg 1982;61:614-7
164. Yamashita M, Shiga T, Matsuki A, Oyama T. Unusual resistance to pancuronium in severely burned patients: case reports. Can Anesth Soc J 1982;29:630-1
165. Marathe PH, Dwersteg JF, Pavlin EG, Haschke RH, Heimbach DM, Slattery JT. Effects of thermal injury on the pharmacokinetics and pharmacodynamics if atracurium in humans. Anesthesiology 1989;70:752-5
166. Meyers EF. Partial recovery from pancuronium neuromuscular blockade following hydrocortisone administration. Anesthesiology 1977;46:148-50
167. Azar I, Kumar D, Betcher AM. Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids. Can Anesth Soc J 1982;29:280-2
168. Doll DC, Rosenberg H. Antagonism of neuromuscular blockage by theophylline. Anesth Analg 1979;58:139-40
169. Daller JA, Erstad B, Rosado L, Otto C, Putnam CW. Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium Crit Care Med 1991; 19:983-5
170. Orenstein E, Matteo RS, Schwartz AE, Silverberg PA, Young WL, Diaz J. The effect of phenytoin on the magnitude and duration of neuromuscular block following atracurium or vecuronium. Anesthesiology 1987;67:191-6
171. Gray H, Slater RM, Pollard BJ. The effect of acutely administered phenytoin on vecuronium-induced neuromuscular blockade. Anesthesia 1989;44:379-81
172. Borden H, Clarke MT, Katz H. The use of pancuronium bromide in patients receiving lithium carbonate. Can Anaesth Soc J 1974;21:79-82
173. Roth S, Ebrahim ZY Resistance to pancuronium in patients receiving carbamazepine. Anesthesiology 1987;66:691-3
174. Coursin DB, Klasek G, Goelzer SL. Increased requirements for continuously infused vecuronium in critically ill patients. Anesth Analg 1989;69:518-21
175. Baraka A. The influence of carbon dioxide on the neuromuscular block caused by tubocurarine chloride in the human subject. Br J Anesth 1964;36:272-8
176. Ono K, Ohta Y, Monta K, Kosaka F. The influence of respiratory-induced acid base changes on the action of non-depolarizing muscle relaxants in rats. Anesthesiology 1988;68:357-62
177. Gencarelli PJ, Swen J, Koot HWJ, Miller RD. The effects of hypercarbia and hypocarbia on pancuronium and vecuronium neuromuscular blockade in anesthetized humans. Anesthesiology 1983;59:376-80
178. Waud BE, Waud DR. Interaction of calcium and potassium with neuromuscular blocking agents. Br J Anesth 1980; 52:863-6
179. Barka A, Yazigi A. Neuromuscular interaction of magnesium with succinylcholine-vecuronium sequence in the eclamptic parturient. Anesthesiology 1987;67:806-9
180. Sinatra RS, Philip BK, Naulty JS, Ostheimer GW. Prolonged neuromuscular blockade with vecuronium in a patient treated with magnesium sulfate. Anesth Analg 1985;64: 1220-2
181. Buzello W, Noeldge G, Kreig N, Brobmann GF. Vecuronium for muscle relaxation in patients with myasthenia gravis. Anesthesiology 1986;64:507-9
182. Gyermek L. Increased potency on non-depolarizing relaxants after poliomyelitis. J Clin Pharmacol 1990;30:170-3
183. Sokoll MD, Gergis SD Antibiotics and neuromuscular function. Anesthesiology 1981;55:148-59
184. Huang KC, Heise A, Shrader AK, Tsueda K. Vancomycin enhances the neuromuscular blockade of vecuronium. Anesth Analg 1990;71:194-6
185. Jedeikin R, Dolgunski E, Kaplan R, Hoffman S. Prolongation of neuromuscular blocking effect of vecuronium by antibiotics. Anesthesia 1987;42:858-60
186. Argov Z, Mastaglia FL. Disorders of neuromuscular transmission caused by drugs. N Engl J Med 1979;301:409-13
187. Chang CC, Chiou LC, Hwang LL, Huang CY Mechanisms of the synergistic actions between organic calcium channel antagonists and various neuromuscular blocking agents. Jpn J Pharmacol 1990;53:285-92
188. Jones RM, Cashman JN, Casson WR, Broadbent MP. Verapamil potentiation of neuromuscular blockade. Anesth Analg 1985;64:1021-5
189. England AJ, Wu X, Richards KM, Redai I, Feldman SA. The influence of cold on the recovery of three neuromuscular blocking agents in man. Anaesthesia 1996;51:236-40
190. Galletly DC. Comparative cutaneous histamine release by neuromuscular blocking agents. Anesth Intensive Care 1986;14:365-9
191. North FC, Kettelkamp N, Hirshman CA. Comparison of cutaneous and in vitro histamine release by muscle relaxants. Anesthesiology 1987;66:543-6
192. Watkins J. Histamine release and atracurium. Br J Anesth 1986;58:19S-22S
193. Hunter JM. Adverse effects of neuromuscular blocking agents. Int Anesth Clin 1988;26:288-301
194. Gronert GA. Malignant hyperthermia. Semin Anesth 1983; 2:197-204
195. Nelson TE, Flewellen EH. The malignant hyperthermia syndrome. N Engl J Med 1983;309:416-8
196. Hund EF, Fogel W, Krieger D, et al. Critical illness polyneuropathy: clinical findings and outcomes of a frequent cause of neuromuscular weaning failure. Crit Care Med 1996;24:1328-33
197. Wijdicks EFM, Litchy W, Harrison BA, Gracey DR. The clinical spectrum of critical illness polyneuropathy. Mayo Clin Proc 1994;69:955-9
198. Bolton CF, Critical illness polyneuropathy. Clin Intensive Care 1992;3:12-14
199. Sladen RN. Neuromuscular blocking agents in the intensive care unit: a two edged sword. Crit Care Med 1995;23: 423-8
200. Watling SM, Dasta JF. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature. Crit Care Med 1994; 22:884-93
201. Rudis MI, Guslits BJ, Peterson EL, et al. Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit. Crit Care Med 1996;24:1749-56
202. Giostra E, Magistris MR, Piazzolato G, et al. Neuromuscular disorder in intensive care units treated with pancuronium bromide. Chest 1994;106:210-20
203. Branney SW, Haenel JB, Moore FA, et al. Prolonged paralysis with atracurium infusion: a case report. Crit Care Med 1994;22:1699-1701
204. Segredo V, Caldwell JE, Matthay MA, et al. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1994;327:524-8
205. Gooch JL, Suchyta MR, Balbierez JM, et al. Prolonged paralysis after treatment with neuromuscular junction blocking agents. Crit Care Med 1991;19:1125-31
206. Margolis BD, Khachikian D, Friedman Y, Garrard C. Prolonged reversible quadriparesis in mechanically ventilated patients who received long-term infusions of vecuronium. Chest 1991;100:877-8
207. Vanderheyden BA, Reynolds HN, Gerold KB, Emanuele T. Prolonged paralysis after long term vecuronium infusion. Crit Care Med 1992;20:304-7
208. Rossiter A, Souney PF, McGowan S, Carvajal P. Pancuronium-induced prolonged neuromuscular blockade. Crit Care Med 1991;19:1583-7
209. Lagasse RS, Katz RI, Petersen M, et al. Prolonged neuromuscular blockade following vecuronium infusion. J Clin Anesth 1990;2:269-71
210. Griffin D, Fairman N, Coursin D, et al. Acute myopathy during treatment of status asthmaticus with corticosteroids and steroidal muscle relaxants. Chest 1992;102:510-4
211. Subramony SH, Carpenter DE, Raju S, et al. Myopathy and prolonged neuromuscular blockade after lung transplant. Crit Care Med 1991;19:1580-2
212. Kaplan P, Rocha W, Sanders DB, et al. Acute steroid tetraplegia following status asthmaticus. Pediatrics 1986; 78:121-3
213. Waclawik AJ, Sufit RL, Beinlich BR, Schutta HS. Acute myopathy with selective degeneration of myosin filaments following status asthmatics treated with methylprednisolone and vecuronium. Neuromusc Disorders 1992; 2:19-26
214. Brun-Buisson C, Gheradi R. Hydrocortisone and pancuronium bromide: acute myopathy during status asthmaticus. Crit Care Med 1988;16:731
215. Danon MJ, Carpenter S. Myopathy with thick filament (myosin) loss following prolonged paralysis with vecuronium during steroid treatment. Muscle Nerve 1991;14: 1131-9
216. Bachman P, Gaussorgues P, Piperno D, et al. Hydrocortisone and pancuronium bromide: acute myopathy during status asthmaticus. Crit Care Med 1988,16:731
217. Panacek EA, Sherman B. Hydrocortisone and pancuronium bromide, acute myopathy during status asthmaticus. Crit Care Med 1988;16:731
218. Williams TJ, O'Heir RE, Czarny D, et al. Acute myopathy in severe acute asthma treated with intravenously administered corticosteroids. Am Rev Respir Dis 1988;137:460-3
219. Dodson BA, Kelly BJ, Braswell LM, Cohen NH. Changes in acetylcholine receptor number in muscle from critically ill patients receiving muscle relaxants: an investigation of the molecular mechanism of prolonged paralysis. Crit Care Med 1995;23:815-21
220. Donati F. Onset of action of relaxants. Can J Anesth 1988; 35:S52-8
221. Cooperman LH. Succinylcholine induced hyperkalemia in neuromuscular disease. JAMA 1970;213:1867
222. Weintraub HD, Heisterkamp DV, Cooperman LH. Changes in plasma potassium concentration after depolarizing blockers in anesthetized man. Br J Anesth 1969;41:1048
223. Schaner PJ, Browen RL, Kirksley TD, Gunther RC, Ritchey CR, Gronert GA. Succinylcholine-induced hyperkalemia in burned patients. Anesth Analg 1969;48:764
224. Gronert GA, Theye RA. Pathophysiology of hyperkalemia induced by Succinylcholine. Anesthesiology 1975;43:89
225. Sosis M, Beoad T, Larijant GE, Marr AT. Comparison of atracurium and d-tubocurarine for prevention of succinylcholine myalgia. Anesth Analg 1987;66:657-9
226. Lehmann H, Lidell J. Human cholinesterase (pseudocholinesterase): genetic variants and their recognition. Br J Anesth 1969;41:235
227. Whittaker M. Genetic aspects of Succinylcholine sensitivity. Anesthesiology 1970;32:143
228. Hunter JM. New neuromuscular blocking drugs. N Engl J Med 1995;332:1691-9
229. Marsh RHK, Chimieliwski AJ, Goat VA. Recovery from pancuronium. Anesthesia 1980;35:1193-6
230. Noeldgc G, Hinaken H, Buzello W. Comparison between the continuous infusion of vecuronium and the intermittent administration of pancuronium and vecuronium. Br J Anesth 1984;56:473-7
231. Gramstad L, Lilleahsen P. Neuromuscular blocking effects of atracurium, vecuronium and pancuronium during bolus and infusion administration. Br J Anesth 1985;57:1052-9
232. Miller RD. Pharmacokinetics of atracurium and other non-depolarizing neuromuscular blocking agents in normal patients and those with renal or hepatic dysfunction. Br J Anesth 1986;58:11S-13S
233. Somogyi AA, Shanks CA, Triggs EJ. Clinical pharmacokinetics of pancuronium bromide. Eur J Clin Pharmacol 1976;10:367-72
234. Agoston S, Vermeer GA, Kersten UW, Meijer DKF. The fate of pancuronium bromide in man. Acta Anesthesiol Scand 1973;17:267-6
235. Bishop MJ. Hemodynamic and gas exchange effects of pancuronium bromide in sedated patients with respiratory failures. Anesthesiology 1984;60:369-71
236. Duvaldestin P, Saada J, Berger JL, D'Hollander A, Desmonts JM. Pharmacokinetics, pharmacodynamics and dose response relationships of pancuronium in control of elderly subjects. Anesthesiology 1982;56:36-40
237. Callahanan DL. Development of resistance to pancuronium in adult
238. McCleod K, Watson MJ, Matteo RS. Pharmacokinetics of pancuronium in patients with normal and impaired renal function. Br J Anesth 1976;48:341-5
239. Vandenbrom RHG, Wierda JMKH. Pancuronium bromide in the intensive care unit: a case of overdose. Anesthesiology 1988;69:996-7
240. Clyburn PA, Marshall RD. Control of ventilation by continuous infusion of pancuronium bromide. Anesthesia 1981; 36:860-2
241. Somogyi AA, Shanks CA, Triggs EJ. Disposition kinetics of pancuronium bromide in patients with total biliary obstruction. Br J Anesth 1977;49:1103-8
242. Duvaldestin P, Agoston S, Henzel D, Kersten UW, Desmonts JM. Pancuronium pharmacokinetics in patients with liver cirrhosis. Br J Anesth 1978;50:1131-6
243. Kelman GR, Kennedy BR. Cardiovascular effects of pancuronium in man. Br J Anesth 1971;43:335-8
244. Agoston S, Salt P, Newton D, Bencini A, Boomsma P, Erdman W. The neuromuscular blocking action of ORG NC45 a new pancuronium derivative, in anesthetized patients: a pilot study. Br J Anesth 1980;52:53S-9S
245. Fahey MR, Morris RB, Miller RD, Sohn YJ, Cronnelly R, Gencarelli P. Clinical pharmacology of ORG NC45 (Norcuron): a new non-depolarizing muscle relaxant. Anesthesiology 1981;55:6-11
246. Torda TA. The "new" relaxants. A review of the clinical pharmacology of atracurium and vecuronium. Anesth Intensive Care 1987;15:72-82
247. Darrah WC, Johnston JR, Mirakhur RK. Vecuronium infusions for prolonged muscle relaxation in the intensive care unit. Crit Care Med 1989;17:1297-1300
248. O'Hara DA, Fragen RJ, Shanks CA. The effects of age on the dose-response curves for vecuronium in adults. Anesthesiology 1985;63:542-4
249. Gordon KL, Reilly CS. Recovery of neuromuscular function after infusion or intermittent bolus dose of atracurium or vecuronium. Br J Anesth 1989;62:269-73
250. Miller RD, Rupp SM, Fisher DM, Cronnelly R, Fahey MR, Sohn YT. Clinical pharmacology of vecuronium and atracurium. Anesthesiology 1984;61:444-53
251. Coursin DB, Klasek G, Goelzer SL. Increased requirements for continuously infused vecuronium in critically ill patients. Anesth Analg 1989;69:519-21
252. Lebrault C, Stnimza P, Henzel, Desmonts JM, Duvaldestin P. Pharmacokinetics and pharmacodynamics of vecuronium in patients with cholestasis Anesthesiology 1985; 63:A314 (Abstract)
253. Hunter JM, Parker CJR, Bell CF, Jones RS, Utting JE. The use of different doses of vecuronium in patients with liver dysfunction. Br J Anesth 1978;57:758-64
254. Lebrault C, Berger JL, D'Hollander AA, Gomeni R, Henzel D, Duvaldestin P. Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. Anesthesiology 1985;62:601-5
255. Lynam DP, Cronnelly R, Arden J, Castagnoli K, Canfell C, Miller RD. The pharmacodynamics and pharmacokinetics of vecuronium in patients with and without renal failure. Anesthesiology 1986;65:A296 (Abstract)
256. Fahey MR, Morris RB, Miller RE, Nguyen T-L, Upton RA. Pharmacokinetics of ORG NC45 (Norcuron) in patients with and without renal failure. Br J Anesth 1981;53: 1049-53
257. Smith, CL, Hunter JM, Jones RS. Vecuronium infusions in patients with renal failure in an ICU. Anesthesia 1987;42:387-93
258. Hunter JM, Jones RS, Utting JE. Comparison of vecuronium, atracurium and tubocurarine in normal patients and in patients with no renal function. Br J Anesth 1984;56:941-51
259. Hughes R. Atracurium: an overview. Br J Anesth 1986;58: 2S-5
260. Wadson AJ, Dogra S, Anand S. Atracurium infusion in the intensive care unit. Br J Anesth 1986;58:64S-67
261. Hutchinson JD, Pinock CA. Use of atracurium infusion. Anesthesia 1984;39:72
262. Hunter JM. Infusions of atracurium and vecuronium in patients with multi system organ failure in the intensive therapy unit. Insights Anesthesiol 1987;1:23-7
263. Ward S, Weatherly BC. Pharmacokinetics of atracurium and its metabolites. Br J Anesth 1986;58:6S-10
264. Fisher DM, Canfell PC, Fahey MR, et al. Elimination of atracurium in humans: Contribution of Hoffman elimination and ester hydrolysis versus organ based elimination. Anesthesiology 1986;41:375-81
265. Ward S, Neill EAM. Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure) Br J Anesth 1983;55:1169-1782
266. Fahey MR, Rupp SM, Fisher DM, et al. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 1984;61:699-702
267. Griffiths RB, Hunter JM, Jones RS. Atracurium infusions in patients with renal failure on an ITU. Anesthesia 1986;41:375-81
268. Hunter JM, Jones RS, Utting JE. Use of atracurium in patients with no renal function. Br J Anesth 1982;54:1251-8
269. Cook DR, Brandom BW, Stiller RL, Woelfel S, Lai A, Slater J. Pharmacokinetics of atracurium in normal and liver failure patients. Anesthesiology 1984;61:A433
270. Tsai SK, Lee C, Mok MS. Atracurium and other non-depolarizing neuromuscular blocking agents in normal patients and those with renal or hepatic dysfunction. Br J Anesth 1987;67:A605
271. Fahey MR, Rupp SM, Canfell C, et al. Effects of renal failure on laudanosine excretion in man. Br. J Anesth 1985;57: 1049-51
272. Parker CJR, Hunter JM. Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis. Br J Anesth 1989;62:177-83
273. Chapple DJ, Miller AA, Wheatley PL. Neurological and cardiovascular effects of laudanosine in conscious and anesthetized dogs. Anesthesiology 1985;63:A311
274. Yate PM, Flynn PJ, Arnold RW, Weatherly BC, Simmonds RJ, Dopson T. Clinical experience and plasma laudanosine concentrations during the infusion of atracurium in the intensive care unit. Br J Anesth 1987;59:211-7
275. Parker CJR, Jones JE, Hunter JM. Disposition of infusions of atracurium and its metabolite laudanosine in patients in renal and respiratory failure in an ITU. Br J Anesth 1988;61:531-40
276. Lawson DL, Paice GM, Glavin EB, et al. A post marketing surveillance study. U.S. study and discussion. Br J Anesth 1989;62:596-600
277. Boyd AH, Eastwood NB, Parker CJ, HunterJM. Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. Br J Anaesth 1996;76:382-8
278. Boyd AH, Eastwood NB, Parker CJR, Hunter JM. Pharmacodynamics of the 1R cis-1'R cis isomer of atracurium (51W89) in health and chronic renal failure. Br J Anesth 1995;74:400-4
279. DeWolf AM, Freeman JA, Scott VL, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth 1996;76:624-8
280. Ornstein E, Lien CA, Matteo RS, et al. Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. Anesthesiology 1996;84:520-5
281. Sorooshian SS, Stafford MA, Eastwood NB, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in the young and elderly patients. Anesthesiology 1996;84: 1083-91
282. Matteo RE, Baccus WW, McDaniel DD, Brotherton WP, Abraham R, Diaz J. Pharmacokinetics and pharmacodynamics of D-tubocurarine and metocurine in the elderly. Anesth Analg 1985;64:23-9
283. Fisher DM, O'Keefe C, Stanski DR, Cronnelly R, Miller RD, Gregory GA. Pharmacokinetics and pharmacodynamics of D-tubocurarine in infants, children, and adults. Anesthesiology 1982;57:203-8
284. Cohen EN, Brewer HW, Smith D. The metabolism and elimination of D-tubocurarine-H3. Anesthesiology 1967; 28:309-17
285. Barnes PK, Thomas VJE, Boyd I, Holloway T. Comparison of the effects of atracurium and tubocurarine on heart rate and arterial pressure in anesthetized man. Br J Anesth 1983;55:91S-94
286. Ghoneim MM, Kramer E, Bannow R, Pandya H, Routh JI. Binding of D-tubocurarine to plasma proteins in normal man and in patients with hepatic or renal disease. Anesthesiology 1973;39:410-5
287. Savarese JJ, Ali HH, Antonio RP. The clinical pharmacology of metocurine: Dimethyltubocurarine revisited. Anesthesiology 1977;47:277-84
288. Brotherton WP, Matteo RS. Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. Anesthesiology 1981;55:273-6
289. Weinstein JA, Matteo RS, Orenstein E, Goldstoff BS, Diaz J. Pharmacokinetics and pharmacodynamics of metocurine in infants, children, and adults. Anesthesiology 1987;67: A615 (Abstract)
290. Meijer DKF, Weitering JG, Vermeer GA, Scaf AHJ. Comparative pharmacokinetics of d-tubocurarine and metocurine in man. Anesthesiology 1979;51:402-7
291. Diffenbach C, Buzello W, Mellinghoff H. Mivacurium chloride - a comparative profile. Acta Anaesthesiol Scand 1995;106:23-5
292. Savarese JJ, Lien CA, Belmont MR, Rubin L. The clinical and basic pharmacology of mivacurium: a short acting non-depolarizing benzylisoquinolinium diester neuromuscular blocking drug. Acta Anaesthesiol Scand 1995; 106:18-22
293. Savarese JJ, Ali HH, Basta SJ, et al. The clinical neuromuscular pharmacology of mivacurium chloride;a short acting nondepolarizing ester neuromuscular blocking drug. Anesthesiology. 1988;68:723-32
294. Savarese JJ, Ali HH, Basta SJ, et al. The cardiovascular effects of mivacurium chloride in patients receiving nitrous oxide-opiate-barbiturate anaesthesia Anesthesiology 1989;70:386-94
295. Erkola O, Rautoma P, Meretoja OA. Mivacurium when preceded by pancuronium becomes a long acting muscle relaxant. Anesthesiology 1996;84:562-5
296. Dahaba AA, Rehak PH, List WF. A comparison of mivacurium infusion requirements between young and elderly patients. Eur J Anaesthesiol 1996;13:43-8
297. Devlin JC, Head-Rapson AG, Parker CJR, Hunter JM. Pharmacodynamics of mivacurium chloride in patients with hepatic cirrhosis. Br J Anaesth 1993;71:227-31
298. Phillips BJ, Hunter JM. Use of mivacurium chloride by constant infusion in the anephric patient Br J Anaesth 1992;68:492-8
299. Cook DR, Freeman JA, Lai AA, et al. Pharmacokinetics of mivacurium, in normal patients and in those with hepatic or renal failure. Br J Anesth 1992;69:580-5
300. Jassere MT. Pipecuronium bromide: a new steroid muscle relaxant - a clinical study. Middle East J Anesthesiol 1995;13:181-95
301. Stanley JC, Mirakhur RK, Bell PF, et al. Neuromuscular effects of pipecuronium bromide. Eur J Anaesth 1991; 8:151-6
302. Khuenl-Brady KS, Reitstatter B, Schlager A, et al. Long-term administration of pancuronium and pipecuronium in the intensive care unit. Anesth Analg 1994;78:1082-6
303. Gyermek L, Cantley EM. Comparison of the onset, spontaneous recovery and train of four fade of the clinical neuromuscular block produced by pancuronium and pipecuronium. International Journal of Clinical Pharmacology and Therapeutics 1994;32:600-5
304. Difenbach C, Mellinghoff H, Buzello W. Variability of pipecuronium neuromuscular blockade. Acta Anaesthesiol Scand 1993;37:189-91
305. Tassonyi E, Pittet JF, Schopgfer CN, et al. Pharmacokinetics of pipecuronium in infants children and adults. Eur J Drug Metab Pharmacokinet 1995;20:203-8
306. Denman WT, Goudsouzian NG, Gelb C. Comparison of neuromuscular, cardiovascular and histamine releasing properties of doxacurium and pipecuronium. J Clin Anesth 1996;8:113-8
307. Cameron EM, Lisbon A, Moorman R, Young JD. Prolonged neuromuscular blockade with pipecuronium in a patient with renal insufficiency. Eur J Anaesthesiol 1994;11:237-9
308. D'Honneur G, Khalil M, Dominique C, et al. Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. Anesth Analg 1993;77:1203-6
309. Wierda JMKH, Szenohradszky J, De Wit APM, et al. The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. Eur J Anaesthesiol 1991;8:451-7
310. Bevan DR. Newer neuromuscular blocking agents. Pharmacol Toxicol 1994;74:3-9
311. Doxacurium. Medical Lett Drugs Ther 1991;33:73-4
312. Cook DR, Freeman JA, Lai AA, et al. Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. Anesth Analg 1991;72:145-50
313. Marik PE. Doxacurium-corticosteroid acute myopathy: another piece to the puzzle. Crit Care Med 1996;24:1266-7
314. Murray MJ, Coursin DB, Scuderi PE, et al. Double blind, ndomized multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular blocking agents. Crit Care Med 1995;23: 450-8
315. Basta SJ, Savarese JJ, Ali HH, et al. Clinical pharmacology of doxacurium chloride. A new long acting nondepolarizing muscle relaxant. Anesthesiology 1988;69:478-86
316. Hunter JM. Rocuronium: the newest aminosteroid neuromuscular blocking drug. Br J Anaesth 1996;76:481-3
317. Khuenl-Brady KS, Sparer H, Puhringer F, Agoston S. Rocuronium bromide in the ICU: dose finding and pharmacokinetics. Eur J Anaesthesiol Suppl 1995;11:79-80
318. Davis L, Jayarajah MJ, Toner CC, Flynn PJ. Evaluation of neuromuscular effects and antagonism of rocuronium bromide: a preliminary report. Eur J Anaesthesiol Suppl 1995;11:65-8
319. Sparr HJ, Luger TJ, Heidegger T, Putsen-Himmer G. Comparison of intubating conditions after rocuronuim and suxamethonium following "rapid sequence induction" with thiopentone in elective cases. Acta Anaesthesiol Scand 1996;40:425-30
320. Mirakhur RK. Dose response and time course of action of rocuronium bromide. Eur J Anaesthesiol Suppl 1995;11: 23-5
321. Tobias JD. Continuous infusion of rocuronium in a pediatric intensive care unit. Can J Anaesth 1996;43:353-7
322. Cooper RA, Mirakhur RK, Wierda JM, Maddineni VR. Pharmacokinetics of rocuronium bromide in patients with and without renal failure. Eur J Anaesthesiol Suppl 1995; 11:43-4
323. Hunter JM. The pharmacokinetics of rocuronium bromide in hepatic cirrhosis. Eur J Anaesthesiol Suppl 1995;11: 39-41